Discovery of a Potent and Orally Bioavailable Melatonin Receptor Agonist
journal contributionposted on 08.03.2021, 06:14 by Yasutaka Hoashi, Takafumi Takai, Yohei Kosugi, Masato Nakashima, Masaharu Nakayama, Keisuke Hirai, Osamu Uchikawa, Tatsuki Koike
To develop potent and orally bioavailable melatonin receptor (MT1 and MT2) agonists, a novel series of 5–6–5 tricyclic derivatives was designed, synthesized, and evaluated. The synthesized indeno[5,4-d][1,3]oxazole, cyclopenta[c]pyrazolo[1,5-a]pyridine, indeno[5,4-d][1,3]thiazole, and cyclopenta[e]indazole derivatives showed potent binding affinities for MT1/MT2 receptors. Further optimization of these derivatives based on their metabolic stability in human hepatic microsomes revealed that (S)-3b ((S)-N-[2-(2-methyl-7,8-dihydro-6H-indeno[5,4-d][1,3]oxazol-8-yl)ethyl]acetamide) was a potent MT1 and MT2 ligand (MT1, Ki = 0.031 nM; MT2, Ki = 0.070 nM) with good metabolic stability in human hepatic microsomes. Moreover, compound (S)-3b showed good BBB permeability in rats, and its in vivo pharmacological effects were confirmed by its sleep-promotion ability in cats.
Read the peer-reviewed publication
vivo pharmacological effectshuman hepatic microsomes3 ] thiazole3 ] oxazole3 ] oxazolindeno [ 5good metabolic stability3b </ b2 </ sub1 </ submetabolic stability>][ 15 -<</ subn </k </h </e </c </>< subpromotion abilitynovel seriesderivatives basedcyclopenta [<>] pyridine>)-< b4 -<070 nm031 nm